Bristol-Myers Squibb Company Earnings Call Transcripts
Fiscal Year 2026
-
Key pipeline programs in oncology, hematology, cardiovascular, and neuroscience are advancing, with pivotal trial readouts expected in the near term. AI-driven trial optimization, robust business development, and a focus on durable growth underpin the strategy. Multiple late-stage assets, including milvexian, COBENFY, and Adempas, are nearing critical milestones.
-
Strong growth in the portfolio is driven by new launches and robust pipeline progress, with double-digit gains in key products and multiple catalysts expected through 2030. Strategic business development and innovation in oncology, neuroscience, and cardiovascular therapies position the company for sustained leadership.
-
The meeting reviewed strong 2025 financials, highlighted a robust growth portfolio, and outlined strategic investments in AI and acquisitions. All board proposals passed with high support, while a shareholder proposal for an independent chair was rejected. Patent cliffs and stock underperformance were key risks discussed.
-
Q1 2026 saw 1% revenue growth to $11.5B, with a 9% increase in the growth portfolio and strong performance from Eliquis, Reblozyl, Breyanzi, and Camzyos. The pipeline advanced with key regulatory milestones and positive pivotal data, and guidance was reaffirmed with performance tracking toward the upper end of ranges.
-
Strong growth is expected from the current portfolio, with CAMZYOS, Opdivo Qvantig, and Cobenfy all performing well and new indications poised to drive further expansion. Multiple late-stage pipeline readouts are anticipated by year-end, including for Milvexian and Admilprant, supporting a strategy focused on long-term, sustainable growth.
-
Strong financial discipline and portfolio growth underpin a robust pipeline, with six pivotal readouts expected in 2026 and over 10 new medicines targeted by 2030. Business development and R&D execution remain top priorities, with major opportunities in neuroscience, oncology, and hematology.
Fiscal Year 2025
-
Growth portfolio delivered double-digit revenue growth, offsetting legacy declines, with key brands like Opdualag, Breyanzi, and Camzyos surpassing $1 billion in annual sales. 2026 guidance projects $46–$47.5 billion in revenue and $6.05–$6.35 EPS, with Eliquis growth in 2026 but a step-down expected in 2027 due to EU patent expirations.
-
The update highlighted a robust hematology pipeline, with CELMoDs and CAR-T therapies showing strong efficacy and safety in multiple myeloma and lymphoma. Key assets are advancing toward pivotal data readouts, with regulatory and commercial strategies well aligned for future growth.
-
Key clinical programs are advancing, with Cobenfy and Camzyos showing strong commercial momentum and new indications in development. AI and efficiency initiatives are driving cost savings and accelerating R&D, while direct-to-patient strategies and robust business development support future growth.
-
Q3 saw 17% year-over-year growth in the growth portfolio, strong sales across oncology, hematology, and cardiovascular products, and raised full-year revenue guidance. Strategic acquisitions and pipeline advancements position the company for sustainable long-term growth.
-
Cell therapy is at an inflection point, with innovation in CAR T platforms, expanded indications, and regulatory changes driving broader access. Manufacturing advances and outpatient delivery have fueled market leadership, while ongoing investments in off-the-shelf and in vivo approaches aim to unlock new opportunities in hematology and immunology.
-
Management highlighted strong Q2 growth, a robust late-stage pipeline, and disciplined financial strategy. Cobenfy's launch is progressing well, with broad access and high prescriber engagement. Key data readouts in oncology, neuroscience, and cardiovascular are expected over the next 12–18 months.
-
Q2 2025 delivered strong revenue and EPS growth, driven by robust demand across key brands and strategic partnerships. Guidance was raised for both revenue and EPS, with continued investment in pipeline and productivity initiatives.
-
Constructive policy engagement and a $40B US investment plan set the stage for growth. Major deals like the BioNTech partnership target leadership in oncology, while launches such as COBENFY and CAMZYOS outperform expectations. A robust pipeline aims for 10 new products and 30 indications by 2030.
-
Leadership is driving growth through portfolio expansion, cost discipline, and strategic M&A, while navigating regulatory and pricing pressures. Key pipeline assets and commercial launches are prioritized, with financial flexibility supporting innovation and resilience.
-
Shareholders heard updates on strong 2024 financials, pipeline progress, and strategic use of AI. All management proposals passed with high approval, while shareholder proposals on financial sustainability and DEI were overwhelmingly rejected. Dividend increases and leadership transitions were also highlighted.
-
Q1 saw robust double-digit growth in the core portfolio, with strong launches for COBENFY and OPDIVO QVANTIG, and multiple regulatory approvals. Full-year revenue and EPS guidance were raised, cost savings initiatives are on track, and the pipeline remains a key focus for long-term growth.
-
Key late-stage readouts are expected in immunology, cardiovascular, and neuroscience, including CAMZYOS, Milvexian, and Cobenfy. The development strategy emphasizes high unmet need, robust phase II data, and optimizing safety and efficacy, with several pivotal trials nearing completion.
-
Strong 2024 performance and a robust pipeline position the company for long-term growth, with major launches like Cobenfy and Camzyos, and significant data readouts expected in 2024. Market expansion, new indications, and next-generation therapies are key strategic focuses.
-
Corrected summary: The conference outlined a multi-year strategy focused on transformational medicines, operational excellence, and disciplined capital allocation. Key growth products and a robust pipeline are expected to drive double-digit revenue growth, with major data readouts and new indications anticipated each year.
Fiscal Year 2024
-
Strong Q4 and full-year 2024 results were driven by double-digit growth in the portfolio, successful launches, and accelerated R&D productivity. 2025 guidance reflects generic headwinds but continued strength in growth brands, with a focus on cost savings and pipeline catalysts.
-
Management outlined a strategy focused on near-term execution and long-term growth, highlighting the COBENFY launch, robust pipeline updates, and continued business development. Financial discipline, portfolio efficiency, and resilience to policy changes underpin the outlook for 2025 and beyond.
-
Strong growth in the portfolio, successful launches, and robust pipeline progress are driving momentum, with major data readouts and product launches expected through 2027. Strategic acquisitions and a $1.5 billion savings initiative support long-term growth, while the company remains focused on execution and resilience amid regulatory changes.
-
The conference highlighted a broadened and prioritized pipeline, with major advances in oncology, neuropsychiatry, immunology, and cardiovascular disease. Key assets like Cobenfy and Milvexian are set for pivotal readouts, while cell therapy and radioligand programs drive future growth.
-
Growth portfolio revenues surged 20% year-over-year, now making up half of total sales, while the launch of Cobenfy in schizophrenia and strong performance across oncology, cardiovascular, and hematology segments drove robust Q3 results. Full-year revenue and EPS guidance were raised, supported by disciplined expense management, strong cash flow, and continued pipeline advancement.
-
The event highlighted robust progress in oncology, with new data supporting dual I-O regimens, expansion into novel modalities, and multiple registrational trials planned or underway. Key programs in lung, prostate, and breast cancer showed promising efficacy and safety, with a focus on overall survival as the primary endpoint.
-
Strong growth in key portfolio products is expected to continue, with major launches like KarXT and expanded access for Sotyktu and Breyanzi driving momentum. Regulatory and policy changes are seen as manageable, and a robust pipeline positions the company for long-term growth.
-
Strong Q2 growth and portfolio momentum are driving a strategic transformation focused on new launches, operational efficiency, and disciplined capital allocation. KarXT is set for a major 2025 launch, with robust pipeline progress in neuroscience and oncology, and confidence in managing IRA impacts.
-
Q2 2024 delivered strong growth in the portfolio, with revenues up 18% year-over-year and EPS at $2.07. Guidance for full-year revenue and EPS was raised, supported by robust performance in oncology, cardiovascular, and cell therapy, and ongoing pipeline momentum.
-
The discussion highlighted a robust clinical pipeline in targeted protein degradation, with multiple CELMoDs and LDDs advancing in myeloma and lymphoma. Novel design strategies, translational insights, and collaborations drive differentiation, with key data expected in 2026.
-
Leadership is driving a focused transformation with resource reallocation, operational simplification, and disciplined capital allocation. Key product launches and pipeline catalysts are prioritized, with strong momentum in immunology, oncology, and cardiovascular. IRA and Part D changes are expected to be neutral overall, with growth clarity emerging over the next 18-24 months.